Skip to main content
AmigoFish

Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets

From The BioCentury Show · · 32 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Notwithstanding the bad start that the Trump administration got off to on FDA, Tim Opler is optimistic that the agency will serve drug developers well, and sees enough good signals that the direction the agency is headed will not bring the difficult regulatory era that many in the industry feared. Opler, a managing director at Stifel, spoke to Editor in Chief Simone Fishburn on The BioCentury Show about why he’s optimistic about FDA, what he sees ahead for capital markets, competition in China, and three areas of innovation he’s focused on -- aging, women's health and the brain.

View full story: https://www.biocentury.com/article/656040

#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment #FDA

00:00 - Introduction 01:30 FDA under Trump 2.0 08:07 State of Capital Markets 13:13 China Competition 17:09 Innovation: Aging, Women’s Health & the Brain

Back to The BioCentury Show · Report a problem